The Empowering Voices: Knowledge and Decision-Making Among People Impacted by Lung Cancer in Europe report, conducted by Lung Cancer Europe (LuCE) with the support of 40 member organisations, features ...

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC). These results were presented ...

Individual results/experiences may vary. He is an expert when it comes to a challenging type of lung cancer. It's called ROS1+ non-small cell lung cancer (NSCLC), and it's known for being aggressive ...

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer ...

has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...

positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on to develop brain mets. Why is this? Doctors aren’t sure.

Priority Review designation underscores the significant advancement taletrectinib may offer patients with ROS1+ NSCLC, for which there remains a high unmet need for new treatment options.

The lung cancer diagnostics market encompasses tools, techniques, and services for detecting lung cancer, including imaging, ...

The NSCLC must not have EGFR, ALK, or ROS1 mutations ... trials that looked at how well it worked to treat the cancer. In the EMPOWER-Lung 1 clinical trial, people received either Libtayo ...